Company Overview and News
Glove sector Upgrade to neutral: The sector has further rerated in 2018 year to date (YTD) and at a weighted average 12-months (12M) forward price earnings (PER) of 33 times, it is a new high. That said, we think current valuation could stay in the second half of 2018 (2H18) supported by the sector’s above-market earnings growth prospects. We now benchmark glove stocks against the sector’s 12M forward PER on our unchanged 2019 earnings per share (EPS )forecasts.
TGLVY 7113 TPGVF 7153 5168 HRGHY
KUALA LUMPUR (June 19): The FBM KLCI fell 0.37% in early trade this morning in line with the retreat at most regional markets, on heightened worries over the trade spat between the world’s two largest economies.
HLFBF KLKBY 2445 PBLOF 4065 1082 5681 BATS 4162 1295 7153 3719
KUALA LUMPUR (June 13): The FBM KLCI pared some of its loss at the midday break today and was down 0.25%, dragged by select blue chips.
PBLOF 7113 5253 BATS TPGVF 4162 AMMHF 1295 7153 2089 7077 5226 1201 PNAGF SPMXF UPBMF 7087 6033 TGLVY PNADF 4588 1015 SPMXY 5819 BSMAF 3719 1818
KUALA LUMPUR (June 12): The FBM KLCI remained under pressure at mid-morning today, dragged by select index-linked blue chips.
HLFBF 7251 UPBMF 1082 7113 5032 TPGVF BATS 4162 7153 5168 2089 9334 TGLVY 5139 0047 5347 3026 0104 0900 6645 TNABY TNABF HRGHY
PETALING JAYA: Top Glove Corp Bhd ’s share price hit a record high of RM10.80 in early trade yesterday as the world’s largest glove manufacturer continued its year-long uptrend on the back of strong rubber glove demand.
TGLVY SPMXY SPMXF 7113 TPGVF 7153 BSMAF 5168 HRGHY 1818
2018-06-18 - Asif
Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...
2018-06-11 - Asif
Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...
2018-06-11 - Asif
Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...